OUSTER INC
OUSTNASDAQ๐ #1920 by market capEarnings Mar 1 ยท PostUS Equity
$23.80โผ $4.36 (โ15.48%)
Market closed ยท at closeTrack OUST
Get earnings, price moves & breaking news on Telegram
24hโผ 15.5%
7dโ
14dโ
30dโ
ytdโ
1yโ
๐ฆMarket Cap
$1.72B
Small Cap
๐Revenue Growth (YoY)
63.7%
High Growth
๐Gross Margin
49.1%
Healthy
๐ตFCF Margin
โ
โ๏ธP/S Ratio
7.7x
Fair
Otter Score
68
Fair
OUSTER INC
OUSTAnalyst Ratings
Price
$23.80
Total
11
Raised
1
Lowered
3
Avg PT
$61.25
H / L
$75 / $53
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
Rosenblatt | Reiterated | Buy | 2026-11-04 | โ | โ |
Cantor Fitzgerald | Upgraded | Neutral โ Overweight | 2026-11-04 | $33.00 | +38.70% |
Amerx | Reiterated | Overweight โ Buy | 2026-11-04 | โ | โ |
Northland Capital Markets | Reiterated | Outperform | 2026-07-21 | โ | โ |
Oppenheimer | Reiterated | Outperform | 2026-07-15 | $57.00 | +139.50% |
WestPark Capital | Reiterated | Buy | 2025-11-05 | โ | โ |
Craig-Hallum | Reiterated | Buy | 2024-08-14 | $10.00 | โ58.00% |
Chardan Capital | Downgraded | Buy โ Neutral | 2024-04-03 | $10.00 | โ58.00% |
Citigroup | Reiterated | Neutral | 2023-08-17 | โ | โ |
Baird | Downgraded | Outperform โ Neutral | 2022-11-08 | โ | โ |
Barclays | Downgraded | Overweight โ Equal Weight | 2022-07-25 | โ | โ |
Institution
Rosenblatt
Reiterated ยท Buy ยท 2026-11-04
โ
โ
Cantor Fitzgerald
Upgraded ยท Neutral โ Overweight ยท 2026-11-04
$33.00
+38.70%
Amerx
Reiterated ยท Overweight โ Buy ยท 2026-11-04
โ
โ
Northland Capital Markets
Reiterated ยท Outperform ยท 2026-07-21
โ
โ
Oppenheimer
Reiterated ยท Outperform ยท 2026-07-15
$57.00
+139.50%
WestPark Capital
Reiterated ยท Buy ยท 2025-11-05
โ
โ
Craig-Hallum
Reiterated ยท Buy ยท 2024-08-14
$10.00
โ58.00%
Chardan Capital
Downgraded ยท Buy โ Neutral ยท 2024-04-03
$10.00
โ58.00%
Citigroup
Reiterated ยท Neutral ยท 2023-08-17
โ
โ
Baird
Downgraded ยท Outperform โ Neutral ยท 2022-11-08
โ
โ
Barclays
Downgraded ยท Overweight โ Equal Weight ยท 2022-07-25
โ
โ
One row per institution ยท price target from the firm's latest published target